title: Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
authors.forename: C
authors.initials: C
authors.lastname: Bourgier
authors.forename: C
authors.initials: C
authors.lastname: Massard
authors.forename: C
authors.initials: C
authors.lastname: Moldovan
authors.forename: J-C
authors.initials: JC
authors.lastname: Soria
authors.forename: E
authors.initials: E
authors.lastname: Deutsch
mesh_terms: D000368:Aged; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011878:Radiotherapy / Q000009:adverse effects*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; C401859:temsirolimus; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus